Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus Mechanism in B Cell Differentiation for Myasthenia Gravis
ChiCTR2200061488Phase 4Not yet recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Jan 2021
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tacrolimus in myasthenia gravis (MG), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Quantitative Myasthenia Gravis (QMG) score. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
tacrolimus
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on ChiCTR2200061488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061488.